U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414953) titled 'A Phase Ib Study of HS-10504 Combined Therapy in NSCLC' on Feb. 10.
Brief Summary: This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Study Start Date: March 30
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Intervention:
DRUG: HS-10504
HS-10504 administered orally every day
DRUG: SHR-A2009
SHR-A2009 administered intravenously
DRUG: HS-20122
HS-20122 administered intravenously
DRUG: HS-20117
HS-20117 administered intravenously
DRUG...